top of page

Treating Metabolic Dysfunction-Associated Steaototic Liver Disease (MASLD) and Metabolic Dysfunction-Associated SteatoHepatitis (MASH) is possible.

Corvida™ is in development to be a best-in-class, orally administered drug for the treatment of MASLD and MASH (Stages F2 through F3) with no worsening of Fibrosis in patients with or without Type 2 Diabetes.
Between 30% - 40% of adults in the US have MASLD.  About 3% - 5% of adults suffer from MASH, a progressive form of MASLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality. Approximately 45% - 75% of people with Type 2 Diabetes have MASLD or MASH.
bottom of page